The purpose of this clinical research study is to learn whether Saxagliptin is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise. The safety of this treatment will also be studied.

Official Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise

Conditions

Diabetes Mellitus, Type 2

Study Type

Interventional

Study Design

Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Further Details

Primary Outcome Measures:

  • To compare the change from baseline in HbA1c achieved with each dose of BMS-477118 versus placebo in treatment naive subjects with type 2 diabetes who have inadequate glycemic control defined as HbA1c >7.0% and <10.0%.

Secondary Outcome Measures:

  • To compare each dose of BMS-477118 versus placebo after 24 weeks of oral administration of double-blind therapy for specific labs.

Study Start

July 2005

Eligibility & Criteria

  • Ages Eligible for Study: 18 Years – 77 Years
  • Genders Eligible for Study: Both

Inclusion Criteria:

  • Type 2 diabetes mellitus
  • Drug naive
  • HbA1c >= 7.0% and <= 10.0% (>10% and <= 12% for open label arm)
  • Fasting C-peptide >= 1 ng/mL
  • Body mass index <= 40 kg/m2

Exclusion Criteria:

  • Symptomatic poorly controlled diabetes
  • Recent cardiac or cerebrovascular event
  • Serum creatinine >= 1.5 mg/dL for males and >= 1.4 mg/dL for females Women of Child Bearing Potential

Total Enrolment

460

Contact Details

Australian Locations:

  • Local Institution, Sydney, New South Wales, Australia
  • Local Institution, Woollongong, New South Wales, Australia
  • Local Institution, Kippa Ring, Queensland, Australia
  • Local Institution, Meadowbrook, Queensland, Australia
  • Local Institution, Brisbane, Queensland, Australia
  • Local Institution, Adelaide, South Australia, Australia
  • Local Institution, Woodville South, South Australia, Australia
  • Local Institution, Perth, Western Australia, Australia

For more information, refer to Bristol-Myers Squibb Clinical Trials

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.